U.S. FDA approves single-pill for HIV treatment

This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.

Sunday 08 Nov 2015 - 13:22 Makkah mean time-26-1-1437 (Image from Gilead Sciences) Maryland, U.S. (IINA) - The U.S. Food and Drug Administration (FDA) announced on Friday that it has approved a new all-in-one pill to treat HIV patients. It noted that the pill includes a new version of the drug tenofovir, which researchers think will help reduce side effects from the multi-drug regimens used for HIV, UPI reported. The pill, called Genvoya, includes doses of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide and is meant especially for patients over age 12 who weigh at least 77 pounds and have not previously been treated for HIV positive virus. In addition to reducing side effects, the drug also was associated with less kidney toxicity and fewer reductions in bone density credited to other medications that contain tenofovir. Patients who already have significant kidney problems, however, should not be treated with the drug, the agency said. "As the HIV patient population ages there is an increased risk for development of age- and treatment-related comorbidities, including low bone mineral density and renal impairment", said Dr. David Wohl, an associate professor of medicine at the University of North Carolina. "This is due to the combination of HIV infection, antiretroviral treatments and the natural aging process". Gilead Sciences, the California-based company which developed Genvoya, conducted four clinical trials with 3,171 participants who were randomly assigned to receive either the new pill or another HIV treatment. The testing was conducted in 21 countries with a broad range of patients. Researchers found in the trials that Genvoya was at least as effective at lowering viral loads in participants, and was associated with less kidney toxicity and fewer decreases in bone density than other drugs, including Stribild, a comparable drug. "Today's approval of a fixed-dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection", said Dr. Edward Cox, director of the Office of Antimicrobial Products at the FDA. AG/IINA